Navigation Links
MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
Date:9/18/2008

REHOVOT, Israel and JERSEY CITY, New Jersey, September 18 /PRNewswire-FirstCall/ -- - A Collaborative Study by Scientists at the Weizmann Institute of Science and Scientists at Sheba Medical Center, With the aid of Rosetta Genomics, Demonstrated That Overexpression of miR-451 Inhibited Growth of Glioblastoma (GBM) Cells

- Furthermore, Combining Imatinib (Gleevec(R)), a Targeted Cancer Drug Approved Treatment of Chronic Myelogenous Leukemia (CML) and Gastrointestinal Stromal Tumors Manufactured by Novartis, With miR-451 had a Synergistic Effect in Inhibiting GBM Growth

- miR-451 was First Disclosed in a Patent Application by Rosetta Genomics and is Currently Under Active Examination

Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today that a collaborative study published by scientists from the Weizmann Institute of Science and scientists at Sheba Medical Center, with the aid of Rosetta Genomics, has demonstrated that a microRNA first disclosed by the company increased the efficacy of Imatinib (Gleevec(R)) in Glioblastoma (GBM), the most common and most aggressive type of primary brain tumor.

"We are excited to be part of this important study led by the renowned scientists from the Weizmann Institute of Science and from the Sheba Medical Center," noted Dr. Dalia Cohen, Chief Scientific Officer at Rosetta Genomics. "MicroRNAs are quickly emerging as major regulators of biological processes and have wide diagnostic and therapeutic potential. Rosetta Genomics' extensive intellectual property portfolio which includes the first ever issued patent relating to microRNAs, as well as patent applications for a large portion of today's known microRNAs, positions us to lead the microRNA space and advance patient care worldwide. Our first microRNA-based products, diagnosing various cancers, are expected to be launched later this year."

In the study, "MIR-451 and Imatinib Mesylate Inhibit the Growth of Glioblastoma Stem Cells", published on
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
2. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
3. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
4. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
5. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
6. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
9. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
10. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
11. The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... More than 1,500 substance abuse prevention and treatment specialists ... Indianapolis Aug. 2-6 for Community Anti-Drug Coalitions ... The week-long training, held at the JW Marriott, will ... biggest public health challenges – youth drug use. ... intensive training opportunity, offering more than 70 half-day and ...
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Pipeline Review, 2015 market research report that provides ... pipeline stage using data sourced from in-house databases, ... on syringes and needles market products pipeline spread ... organizations supported with 73 tables and 5 figures ...
(Date:7/31/2015)... , July 31, 2015  Boston Children,s Hospital ... from 3D printing of their anatomy before undergoing ... cerebrovascular malformations (abnormalities in the brain,s blood vessels) ... online today in the Journal of Neurosurgery: ... 3D printing and synthetic resins to create custom, ...
Breaking Medicine Technology:Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 53D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4
... , , , , , , , , , ... and LAUSANNE, Switzerland , February 4 ... Debiopharm Group (Debiopharm), a Swiss-based global,biopharmaceutical group of companies with ... medical needs, announce the launch by,Ipsen in France ...
... , REDWOOD CITY, Calif. , Feb. ... financial results for the year ended December 31, 2009 , which ... cash flow positive. , Total revenue for the fourth quarter of 2009 ... in the fourth quarter of 2008.  Product revenue from the Onco type ...
Cached Medicine Technology:Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 2Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 3Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 4Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 5Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 6Genomic Health Announces Year-End 2009 Financial Results 2Genomic Health Announces Year-End 2009 Financial Results 3Genomic Health Announces Year-End 2009 Financial Results 4Genomic Health Announces Year-End 2009 Financial Results 5Genomic Health Announces Year-End 2009 Financial Results 6Genomic Health Announces Year-End 2009 Financial Results 7Genomic Health Announces Year-End 2009 Financial Results 8Genomic Health Announces Year-End 2009 Financial Results 9Genomic Health Announces Year-End 2009 Financial Results 10Genomic Health Announces Year-End 2009 Financial Results 11Genomic Health Announces Year-End 2009 Financial Results 12
(Date:7/31/2015)... ... , ... There’s no better way to enjoy the summer weather than by ... next meal, making July the most appropriate to be National Hot Dog Month. King ... Make the next cookout different than the ones in the past. Celebrate National Hot ...
(Date:7/31/2015)... ... 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust ... the exam easy and painless. MDLinx offers thousands of board-exam style questions and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique pastries and delicious ... with custom designs, making life just a little bit sweeter for newlyweds. A ... each customer who orders one. , The bakery provides a full line of custom ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... one-day event geared to patients and family members, medical professionals, and researchers, covering ... mesothelioma experts. The conference is a collaborative effort between the Mesothelioma Applied Research ...
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and Peach State ... Girl Scout "Be a Friend First" program. Representatives from Peach State Health Plan presented ... State Health Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2
... will help treat baldness by growing new hair follicle cells//. ... hair follicles from the back of the neck, multiplying them ... BBC News. ,It initially tested the treatment on ... hair. They are to test the treatment on 20 more ...
... group of pioneering psychiatrists who worked in Saskatchewan, Canada in ... Dyck, who is working on it for the last 5 ... the University of Alberta, sited records of the psychiatrists' research, ... single dose of the hallucinogenic drug LSD, administered in a ...
... A team of scientists from the University of Adelaide, ... world breakthrough in understanding how bacterial toxins cause// severe ... Adrienne Paton from the University of Adelaide’s School of ... potent bacterial toxin kills cells by inactivating an essential ...
... Paswan promises a new policy for the poor that will ... tuberculosis, AIDS and cancer. ,"By Jan 1 we ... will offer free medication to the poor," Paswan said in ... with the help of the drug manufacturers who have agreed ...
... surgeons at The Methodist Hospital shows unprecedented improvements in ... Lucentis? for wet// age-related macular degeneration (AMD), according to ... Medicine. AMD is a major cause of central visual ... blindness in people over 60. ,Dr. David ...
... revealed that behavioral therapies can benefit children who have problems ... ,The American Academy of Sleep Medicine (AASM) appointed a ... babies and toddlers. ,According to study author Jodi ... have shown 20 to 30 percent of young children have ...
Cached Medicine News:Health News:Effective Cure for Alcoholism – A single dose of LS 2Health News:Effective Cure for Alcoholism – A single dose of LS 3Health News:Scientists Make World Breakthrough 2Health News:Free Medicines, Health Insurance for Poor Soon: Paswan 2Health News:Results for Wet Age-Related Macular Degeneration Show Significant Vision Improvements 2
Inquire...
... More than 1 million people are ... a majority of these patients never seek ... The TRIVEX* System can offer them an ... vein removal, (stab avulsion or hook phlebectomy), ...
...
... of experience, the SSD-1000 is a high ... uses our advanced technologies and over 5 ... same technology as our more expensive systems, ... a compact and mobile setting., We also ...
Medicine Products: